Drug Discovery
​Leveraging molecular interactions to develop therapeutic compounds
Challenge
Drug discovery faces many challenges, encompassing target identification, compound screening, and optimization of drug candidates for efficacy and safety. Accurate characterization of molecular interactions within complex biological systems is essential for understanding disease mechanisms and identifying potential therapeutic targets. Additionally, navigating the vast chemical space to find lead compounds with desirable pharmacological properties presents a significant hurdle.
Solutions
Our SPR devices provide invaluable insights into molecular interactions, offering researchers a precise understanding of candidate compounds' binding kinetics and affinity. Our technology facilitates efficient screening and selection processes, enabling the identification of promising leads early in the drug discovery journey. With Affinite Instruments' SPR devices, researchers can navigate drug discovery challenges with confidence, accelerating the development of innovative therapeutics
Compatible Targets
Real-World Applications
Identifying biological targets
The identification of biological targets is a crucial phase in drug discovery where researchers aim to pinpoint specific molecules, such as proteins or nucleic acids, that play key roles in disease processes. By elucidating binding affinities and specificity, studies between biomolecules and small molecules provide invaluable insights into potential drug targets. Leveraging SPR and innovative approaches, researchers can unravel complex biological interactions, paving the way for the development of novel therapeutic interventions across various diseases and conditions.
Efficient lead screening
SPR's label-free nature minimizes the need for extensive sample preparation, making it an ideal technique for small-scale lead screening efforts in drug discovery endeavors. By immobilizing target proteins, researchers can screen small compound leads to identify potential drug candidates based on their binding affinity and kinetics. This label-free technique allows for rapid evaluation of multiple compounds, aiding in the efficient selection of promising leads for further optimization.
Bioanalytical DNA Detection
Cytokine release syndrome is a form of systemic inflammatory response syndrome that arises as a complication of some diseases or infections, and is also an adverse effect of some monoclonal antibody drugs and other treatments. Severe cases have been called “cytokine storms” and can be fatal. Understanding the mechanism of inflammation is important. Here, the P4SPR was deployed to investigate the binding of a gene (EBI3) to IL-6, a pro-inflammatory cytokine. This unexpected observation could lead to a new therapeutic biologic for autoimmune diseases.
